ARTICLE | Clinical News
Rifaximin rifamycin antibiotic regulatory update
January 7, 2002 8:00 AM UTC
SLXP submitted an NDA to the FDA for its Rifaximin rifamycin antibiotic to treat travelers' diarrhea. SLXP licensed Canadian and U.S. rights to Rifaximin from Alfa Wassermann S.p.A. (Bologna, Italy), ...